[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604091":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":11,"id":45,"slug":11,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University of Baghdad","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Suprachoroidal Triamcinolone treatment arm","EXPERIMENTAL",null,[13],"Drug: Suprachoroidal triamcinolone acetonide injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Suprachoroidal triamcinolone acetonide injection","For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Mohammed Suhail Al-Salam","CONTACT","+964 790 183 6367","mohammedsuhail@uomustansiriyah.edu.iq",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Ibn Al-Haitham Eye Teaching Hospital","RECRUITING","Baghdad","10064","Iraq",{"type":34,"coordinates":35},"Point",[36,37],44.40088,33.34058,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Mohammed Mutar","Medical Doctor","100604091",false,"NCT07145008","Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon","Inclusion Criteria:\n\n* Non-infectious uveitis complicated with macular edema\n* Uveitic macular edema of less than four months' duration\n* Macular edema persisted despite lack of intra-ocular inflammation\n* No response to posterior sub-Tenon triamcinolone acetonide injections\n\nExclusion Criteria:\n\n* Those with epiretinal membrane-associated macular edema\n* Below 18 years","ALL","18 Years",{"count":53,"type":54},20,"ESTIMATED","INTERVENTIONAL",[57],"EARLY_PHASE1","The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection).\n\nThe main questions it aims to answer are:\n\nDoes vision improve on the eye chart after the injection?\n\nDoes the injection lower retinal swelling (reduction in thickness) within 3 months?\n\nParticipants will:\n\nHave a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT).\n\nReceive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring.\n\nReturn for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans.\n\nContact the clinic if they notice pain, redness, new floaters, or worsening vision.",[60,61],"Macular Edema (ME)","Non Infectious Uveitis",[63,64,65,66],"Suprachoroidal Triamcinolone","Macular Edema","Non infectious uveitis","Subtenon resistant","2025-08-21",{"date":69,"type":70},"2025-08-28","ACTUAL",{"date":72,"type":70},"2024-09-01",{"date":74,"type":54},"2026-12-01",{"name":5,"class":6},1]